将要访问
http://www.gilead.com/news/press-releases/2014/6/gilead-announces-phase-3-data-showing-that-the-fixeddose-combination-of-ledipasvirsofosbuvir-achieved-100-percent-sustained-virologic-response-svr12-among-patients-with-chronic-hepatitis-c-in-japan
此网页未在微博完成域名备案，可能存在内容风险。
如要继续访问，请注意您的隐私及财产安全。